Publication date: Available online 19 December 2015
Source:Critical Reviews in Oncology/Hematology
Author(s): Omar Al Ustwani, Neha Gupta, Hatoon Bakhribah, Elizabeth Griffiths, Eunice Wang, Meir Wetzler
Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by B or T lineage. Here we cover the clinical manifestations, pathophysiology and therapy for ALL. Additionally, we will discuss the evidence for minimal residual disease assessment, novel molecular targets and newly developed targeted therapies. The separation of ALL into Philadelphia chromosome positive and recently into Philadelphia-like disease represents the most exciting developments in this disease. Finally, the advent of new immunotherapeutic approaches led us to predict that in few years, ALL therapy might be based heavily on non-chemotherapeutic approaches.
from Cancer via ola Kala on Inoreader http://ift.tt/1MoUETv
via IFTTT
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1OfXOdw
via IFTTT
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/22hJjjL
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου